Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  40.00 0.51% 7,920.00 7,919.00 7,921.00 7,936.00 7,805.00 7,805.00 106,306 08:42:50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.4 1,167.2 77.7 99.9 103,903

AstraZeneca's Lynparza Recommended by EU for Ovarian, Prostrate Cancer

21/09/2020 8:02am

Dow Jones News


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Aug 2020 to Oct 2020

Click Here for more Astrazeneca Charts.

By Anthony O. Goriainoff

 

AstraZeneca PLC said on Monday that its Lynparza drug has been recommended for approval in the European Union as first-line maintenance treatment for HRD-positive advanced ovarian cancer, and that it has also been recommended for marketing authorization by the EU for patients with metastatic castration-resistant prostate cancer.

The FTSE 100-listed drug maker also said that results from a prespecified exploratory analysis of the positive ADAURA phase 3 trial showed its Tagrisso drug demonstrated a clinically-meaningful improvement in central nervous system disease-free survival in patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection. The company said Tagrisso also reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage epidermal growth factor receptor-mutated lung cancer.

The company said that advanced ovarian cancer patients treated with Lynparza and drug bevacizumab lived without disease progression for a median of 37.2 months versus 17.7 months for bevacizumab alone.

The pharmaceutical company also said that for patients with advanced ovarian cancer, the primary aim of first-line treatment is to delay disease progression for as long as possible with the intent to achieve long-term remission.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

September 21, 2020 02:47 ET (06:47 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 08:57:55